Lazard survey: Uptick expected for bolt-on M&A, broader use of AI

New results from Lazard’s annual survey of biopharma leaders and investors paint a cautiously optimistic picture, envisioning an uptick in bolt-on M&A activity and a broader impact from artificial intelligence and machine learning technologies.

The 2024 Lazard Global Biopharmaceutical Leaders Study also suggests that although uncertainties around macroeconomics and the U.S. election may lead to continued volatility, dealmakers are finding ways to overcome a disconnect in how potential buyers and sellers value biotechs...